Swertia species, particularly Swertia chirayita, is well- recognized in traditional medicines because of its wide-ranging pharmacological activities. These therapeutic properties are primarily attributed to bioactive phytochemicals and alkaloids, including amarogentin, mangiferin, and swertiamarin. Despite promising pre-clinical evidence, clinical translation of Swertia-based therapeutics is limited by poor aqueous solubility, low oral bioavailability, rapid metabolism, and inadequate target specificity. This review examines the convergence of traditional Swertia-based ethnomedicine with modern nanotechnology-driven drug-delivery approaches to address underlying challenges. Several nanoformulation strategies, including green-synthesis of metal nanoparticles, polymeric nanoparticles, solid lipid nanoparticles, liposomes, phytosomes, nanoemulsions, and stimuli-responsive nanocarriers, are deliberated. The possibility of enhancing solubility, stability, pharmacokinetics, targeted delivery, and controlled release of Swertia phytoconstituents has been critically examined. Additionally, mechanistic insights underlying improved therapeutic performance, cellular uptake pathways, and pH- or tumor-responsive release mechanisms are highlighted. Furthermore, the review addresses the key translational challenges, including plant material standardization, scalability, good manufacturing practice (GMP) compliance, long-term toxicity and safety evaluation, regulatory considerations, and existing gaps in mechanistic understanding. Finally, future perspectives are outlined, emphasising the development of hybrid and multifunctional nanocarriers, theranostic platforms, and personalized Swertia-based nanomedicines. By integrating ethnopharmacological knowledge with nanotechnological advances, this review aims to provide a comprehensive framework for advancing Swertia-derived phytochemicals toward clinically viable therapeutic applications.
Yadav et al. (2026) studied this question.